AlphaGrep UK’s Sarepta Therapeutics SRPT Stock Holding History

AlphaGrep UK’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,449	Closed	-$249K	–	940
2026 Q1	$249K	Buy	+11,449	New	+$222K	0.07%	600

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaGrep UK's SRPT Position: Q2 2026 in Review

AlphaGrep UK sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 11,449 shares — an estimated $249K sold.

AlphaGrep UK first reported a position in SRPT in Q1 2026 and held it in 1 quarter. The position peaked at $249K in Q1 2026. 298 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

AlphaGrep UK reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 11,449 Sarepta Therapeutics shares in Q2 2026, an estimated $249K.
AlphaGrep UK first reported a position in Sarepta Therapeutics in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Sarepta Therapeutics position peaked at $249K in Q1 2026.
298 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.